{"id":"https://openalex.org/W2133206502","doi":"https://doi.org/10.1016/j.lungcan.2015.03.010","title":"Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer","display_name":"Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer","alternate_titles":[],"publication_year":2015,"publication_date":"2015-03-29","ids":{"openalex":"https://openalex.org/W2133206502","doi":"https://doi.org/10.1016/j.lungcan.2015.03.010","mag":"2133206502","pmid":"https://pubmed.ncbi.nlm.nih.gov/25891541"},"language":"en","primary_location":{"id":"doi:10.1016/j.lungcan.2015.03.010","doi":"https://doi.org/10.1016/j.lungcan.2015.03.010","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.lungcan.2015.03.010","pdf_url":null,"source":{"id":"https://openalex.org/S100767427","display_name":"Lung Cancer","issn_l":"0169-5002","issn":["0169-5002","1872-8332"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Lung Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2133206502"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.lungcan.2015.03.010","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078287634","display_name":"Makoto Nishio","orcid":"https://orcid.org/0000-0003-4969-4165","observed_orcids":["https://orcid.org/0000-0003-4969-4165"]},"institutions":[{"id":"https://openalex.org/I4210137039","display_name":"The Cancer Institute Hospital","ror":"https://ror.org/03md8p445","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210137039"]},{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Makoto Nishio","raw_affiliation_strings":["Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Electronic address: mnishio@jfcr.or.jp","Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Electronic address: mnishio@jfcr.or.jp","institution_ids":["https://openalex.org/I4210137039","https://openalex.org/I42570316"]},{"raw_affiliation_string":"Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan","institution_ids":["https://openalex.org/I4210137039","https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045832805","display_name":"Atsushi Horiike","orcid":"https://orcid.org/0000-0002-1632-3125","observed_orcids":["https://orcid.org/0000-0002-1632-3125"]},"institutions":[{"id":"https://openalex.org/I4210137039","display_name":"The Cancer Institute Hospital","ror":"https://ror.org/03md8p445","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210137039"]},{"id":"https://openalex.org/I42570316","display_name":"Japanese Foundation For Cancer Research","ror":"https://ror.org/00bv64a69","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I42570316"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Atsushi Horiike","raw_affiliation_strings":["Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Electronic address: atsushi.horiike@jfcr.or.jp","Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Electronic address: atsushi.horiike@jfcr.or.jp","institution_ids":["https://openalex.org/I4210137039","https://openalex.org/I42570316"]},{"raw_affiliation_string":"Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan","institution_ids":["https://openalex.org/I4210137039","https://openalex.org/I42570316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025707585","display_name":"Haruyasu Murakami","orcid":"https://orcid.org/0000-0003-2416-546X","observed_orcids":["https://orcid.org/0000-0003-2416-546X"]},"institutions":[{"id":"https://openalex.org/I4210088324","display_name":"Shizuoka Cancer Center","ror":"https://ror.org/0042ytd14","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210088324"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Haruyasu Murakami","raw_affiliation_strings":["Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Electronic address: ha.murakami@scchr.jp","Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Electronic address: ha.murakami@scchr.jp","institution_ids":["https://openalex.org/I4210088324"]},{"raw_affiliation_string":"Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan","institution_ids":["https://openalex.org/I4210088324"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032337115","display_name":"Nobuyuki Yamamoto","orcid":"https://orcid.org/0000-0002-7342-0853","observed_orcids":["https://orcid.org/0000-0002-7342-0853"]},"institutions":[{"id":"https://openalex.org/I4210088324","display_name":"Shizuoka Cancer Center","ror":"https://ror.org/0042ytd14","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210088324"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Nobuyuki Yamamoto","raw_affiliation_strings":["Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Electronic address: nbyamamo@wakayama-med.ac.jp","Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Electronic address: nbyamamo@wakayama-med.ac.jp","institution_ids":["https://openalex.org/I4210088324"]},{"raw_affiliation_string":"Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan","institution_ids":["https://openalex.org/I4210088324"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083384491","display_name":"Hiroyasu Kaneda","orcid":"https://orcid.org/0000-0002-7696-2391","observed_orcids":["https://orcid.org/0000-0002-7696-2391"]},"institutions":[{"id":"https://openalex.org/I916559398","display_name":"Kindai University","ror":"https://ror.org/05kt9ap64","country_code":"JP","type":"education","lineage":["https://openalex.org/I916559398"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Hiroyasu Kaneda","raw_affiliation_strings":["Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan. Electronic address: kaneda_h@dotd.med.kindai.ac.jp","Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan. Electronic address: kaneda_h@dotd.med.kindai.ac.jp","institution_ids":["https://openalex.org/I916559398"]},{"raw_affiliation_string":"Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan","institution_ids":["https://openalex.org/I916559398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100648645","display_name":"Kazuhiko Nakagawa","orcid":"https://orcid.org/0000-0003-1284-9776","observed_orcids":["https://orcid.org/0000-0003-1284-9776"]},"institutions":[{"id":"https://openalex.org/I916559398","display_name":"Kindai University","ror":"https://ror.org/05kt9ap64","country_code":"JP","type":"education","lineage":["https://openalex.org/I916559398"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kazuhiko Nakagawa","raw_affiliation_strings":["Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan. Electronic address: nakagawa@med.kindai.ac.jp","Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan. Electronic address: nakagawa@med.kindai.ac.jp","institution_ids":["https://openalex.org/I916559398"]},{"raw_affiliation_string":"Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan","institution_ids":["https://openalex.org/I916559398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069589468","display_name":"Hidehito Horinouchi","orcid":"https://orcid.org/0000-0001-9090-801X","observed_orcids":["https://orcid.org/0000-0001-9090-801X"]},"institutions":[{"id":"https://openalex.org/I4210087348","display_name":"National Cancer Centre Japan","ror":"https://ror.org/0025ww868","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348"]},{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Hidehito Horinouchi","raw_affiliation_strings":["Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: hhorinou@ncc.go.jp","Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: hhorinou@ncc.go.jp","institution_ids":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]},{"raw_affiliation_string":"Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan","institution_ids":["https://openalex.org/I4405285273"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Masaki Nagashima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Masaki Nagashima","raw_affiliation_strings":["Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: nagashima.masaki.ns@daiichisankyo.co.jp","Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: nagashima.masaki.ns@daiichisankyo.co.jp","institution_ids":["https://openalex.org/I4210104626"]},{"raw_affiliation_string":"Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Masaru Sekiguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Masaru Sekiguchi","raw_affiliation_strings":["Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: sekiguchi.masaru.f3@daiichisankyo.co.jp","Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: sekiguchi.masaru.f3@daiichisankyo.co.jp","institution_ids":["https://openalex.org/I4210104626"]},{"raw_affiliation_string":"Clinical Development Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5105411153","display_name":"Tomohide Tamura","orcid":"https://orcid.org/0000-0003-3601-8889","observed_orcids":["https://orcid.org/0000-0003-3601-8889"]},"institutions":[{"id":"https://openalex.org/I4210087348","display_name":"National Cancer Centre Japan","ror":"https://ror.org/0025ww868","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348"]},{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Tomohide Tamura","raw_affiliation_strings":["Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: tamuratomohide@gmail.com","Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: tamuratomohide@gmail.com","institution_ids":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]},{"raw_affiliation_string":"Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan","institution_ids":["https://openalex.org/I4405285273"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5025707585","https://openalex.org/A5032337115","https://openalex.org/A5045832805","https://openalex.org/A5069589468","https://openalex.org/A5078287634","https://openalex.org/A5083384491","https://openalex.org/A5100648645","https://openalex.org/A5105411153"],"corresponding_institution_ids":["https://openalex.org/I4210087348","https://openalex.org/I4210088324","https://openalex.org/I4210104626","https://openalex.org/I4210137039","https://openalex.org/I42570316","https://openalex.org/I4405285273","https://openalex.org/I916559398"],"apc_list":{"value":3390,"currency":"USD","value_usd":3390},"apc_paid":{"value":3390,"currency":"USD","value_usd":3390},"fwci":4.4936,"has_fulltext":false,"cited_by_count":41,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.95159516,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"88","issue":"3","first_page":"275","last_page":"281"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.00559999980032444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her3","display_name":"HER3","score":0.7639999985694885},{"id":"https://openalex.org/keywords/anti-her3-monoclonal-antibody","display_name":"anti-HER3 monoclonal antibody","score":0.8989999890327454},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9269999861717224},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8090000152587891},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6919999718666077},{"id":"https://openalex.org/keywords/gefitinib-resistance","display_name":"gefitinib resistance","score":0.7549999952316284},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7540000081062317},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.890999972820282},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8569999933242798},{"id":"https://openalex.org/keywords/egfr-activating-mutations","display_name":"EGFR activating mutations","score":0.640999972820282},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.843999981880188}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9629247188568115},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8879668712615967},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7422535419464111},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6666292548179626},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.651063084602356},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6423870921134949},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6114302277565002},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5849108695983887},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5776591300964355},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4350668787956238},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.420957088470459},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3719790577888489},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3652651906013489}],"mesh":[{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000080908","descriptor_name":"Broadly Neutralizing Antibodies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020893","descriptor_name":"Receptor, ErbB-3","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D020893","descriptor_name":"Receptor, ErbB-3","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057134","descriptor_name":"Antibodies, Neutralizing","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.lungcan.2015.03.010","doi":"https://doi.org/10.1016/j.lungcan.2015.03.010","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.lungcan.2015.03.010","pdf_url":null,"source":{"id":"https://openalex.org/S100767427","display_name":"Lung Cancer","issn_l":"0169-5002","issn":["0169-5002","1872-8332"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Lung Cancer","raw_type":"journal-article"},{"id":"pmid:25891541","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25891541","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Lung cancer (Amsterdam, Netherlands)","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1016/j.lungcan.2015.03.010","doi":"https://doi.org/10.1016/j.lungcan.2015.03.010","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.lungcan.2015.03.010","pdf_url":null,"source":{"id":"https://openalex.org/S100767427","display_name":"Lung Cancer","issn_l":"0169-5002","issn":["0169-5002","1872-8332"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Lung Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W1544959878","https://openalex.org/W1582187753","https://openalex.org/W1964321121","https://openalex.org/W1994435019","https://openalex.org/W1995097511","https://openalex.org/W1995119153","https://openalex.org/W2004439203","https://openalex.org/W2010662888","https://openalex.org/W2017081079","https://openalex.org/W2018340304","https://openalex.org/W2019607817","https://openalex.org/W2029633750","https://openalex.org/W2036253797","https://openalex.org/W2049511540","https://openalex.org/W2053673624","https://openalex.org/W2066659324","https://openalex.org/W2076668534","https://openalex.org/W2090685720","https://openalex.org/W2097026987","https://openalex.org/W2112853929","https://openalex.org/W2114286868","https://openalex.org/W2124511021","https://openalex.org/W2128477683","https://openalex.org/W2132540363","https://openalex.org/W2144180913","https://openalex.org/W2159639650","https://openalex.org/W2161338384","https://openalex.org/W2168340462","https://openalex.org/W2399195461","https://openalex.org/W2408927291","https://openalex.org/W2461360472","https://openalex.org/W2787560615","https://openalex.org/W3127611755","https://openalex.org/W6748520944"],"related_works":["https://openalex.org/W2315090353","https://openalex.org/W2583783944","https://openalex.org/W2313010431","https://openalex.org/W2766948475","https://openalex.org/W2533433146","https://openalex.org/W1537035141","https://openalex.org/W1994435019","https://openalex.org/W2327172443","https://openalex.org/W3088656828","https://openalex.org/W2890500299"],"abstract_inverted_index":{"OBJECTIVES:":[0],"Human":[1],"epidermal":[2,51],"growth":[3,52],"factor":[4,53],"receptor":[5],"3":[6,132],"(HER3)":[7],"is":[8,18],"a":[9,40,256],"key":[10],"dimerization":[11],"partner":[12],"for":[13,231,241],"HER":[14,24],"family":[15,25],"members":[16],"and":[17,35,91,115,161,180,208,237,260,275],"associated":[19],"with":[20,48,59,75,79,270],"resistance":[21],"to":[22,136,214],"other":[23],"receptor-targeted":[26],"therapeutics.":[27],"This":[28,71,105],"study":[29,72,107],"evaluated":[30],"the":[31,147,188,232,242,276,279],"safety,":[32],"tolerability,":[33],"pharmacokinetics":[34,160,211],"efficacy":[36,259,277],"of":[37,101,150,248,278],"patritumab":[38,126,151,171],"(U3-1287),":[39],"fully":[41],"human":[42],"anti-HER3":[43],"monoclonal":[44],"antibody,":[45],"in":[46,57,134,154,217,263,268,284],"combination":[47,269,280],"erlotinib,":[49],"an":[50],"receptor-tyrosine":[54],"kinase":[55],"inhibitor":[56],"patients":[58,74,123,145,169,285],"previously":[60],"treated":[61],"advanced":[62],"non-small":[63],"cell":[64],"lung":[65],"cancer":[66],"(NSCLC).":[67],"PATIENTS":[68],"AND":[69],"METHODS:":[70],"enrolled":[73],"stage":[76],"IIIB/IV":[77],"NSCLC":[78],"Eastern":[80],"Cooperative":[81],"Oncology":[82],"Group":[83],"performance":[84],"status":[85],"0-1,":[86],"life":[87],"expectancy":[88],">3":[89],"months":[90],"who":[92],"had":[93],"progressed":[94],"after":[95],"at":[96,172],"least":[97],"one":[98],"prior":[99,287],"course":[100],"chemotherapy":[102],"(excluding":[103],"erlotinib).":[104],"open-label":[106],"included":[108],"two":[109],"parts:":[110],"dose":[111,116,149,190],"escalation":[112],"(Part":[113,118],"1)":[114],"expansion":[117],"2).":[119],"In":[120,142],"Part":[121,143,155],"1,":[122],"received":[124,146,170],"intravenous":[125],"9":[127,173],"or":[128,176,201],"18":[129,177],"mg/kg":[130,174,178],"every":[131],"weeks":[133],"addition":[135],"per-oral":[137],"erlotinib":[138,271],"150":[139],"mg/day":[140],"daily.":[141],"2,":[144],"recommended":[148],"as":[152],"determined":[153],"1.":[156],"Adverse":[157],"event":[158],"rates,":[159],"tumor":[162,264],"responses":[163],"were":[164,185,199,205,212],"determined.":[165],"RESULTS:":[166],"Twenty-four":[167],"Japanese":[168],"(n=3)":[175],"(n=21),":[179],"erlotinib.":[181],"No":[182],"dose-limiting":[183],"toxicities":[184],"reported,":[186],"indicating":[187],"maximum-tolerated":[189],"was":[191,227,272,281],"not":[192,254],"reached.":[193],"The":[194,220],"most":[195],"frequent":[196],"adverse":[197],"events":[198],"gastrointestinal":[200],"skin":[202],"toxicities,":[203],"which":[204],"generally":[206],"mild":[207],"manageable.":[209],"Patritumab":[210,267],"similar":[213],"those":[215],"reported":[216],"previous":[218],"studies.":[219],"median":[221],"progression-free":[222],"survival":[223],"(95%":[224],"confidence":[225],"interval)":[226],"44.0":[228],"(22.0-133.0)":[229],"days":[230,240],"EGFR":[233],"wild-type":[234],"group":[235,245],"(n=9)":[236],"107.0":[238],"(74.0-224.0)":[239],"EGFR-activating":[243],"mutation":[244],"(n=13).":[246],"Evaluation":[247],"biomarkers":[249],"by":[250],"immunohistochemical":[251],"analysis":[252],"did":[253],"indicate":[255],"relationship":[257],"between":[258],"HER3":[261],"expression":[262],"tissues.":[265],"CONCLUSION:":[266],"well":[273],"tolerated":[274],"encouraging,":[282],"especially":[283],"where":[286],"gefitinib":[288],"treatment":[289],"failed.":[290]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2133206502","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
